On June 9, 2026, Vistagen Therapeutics announced that its fasedienol nasal spray for treating social anxiety disorder has met the required minimum patient exposure standards for long-term treatment under international safety regulations. This event is significant from an investor perspective as it shows progress in their clinical program.